Vaccines from age 5?
September 21, 2021
164,946
4,357
5,095
5.73%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around September 21, 2021
See what was published immediately before and after this episode.
24:39Now PlayingVaccines from age 5?
YouTube Description
as posted by the channelPfizer for 5 to 11 year olds
5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses
Companies plan to submit these data to the FDA, EMA and other regulatory agencies
Results in children under 5 years of age are expected as soon as later this year
N = 4,500, Finland, Poland, Spain, US
Two dose, 21 days apart
10 ug, not 30 ug
Similar results to 30 ug in 15 to 25 year olds
Phase 2/3 trial
Side effects reported with the vaccine include:
A severe allergic reaction would usually occur within a few minutes to one hour
Difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness
Myocarditis and pericarditis have occurred in some people who have received the vaccine.
In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine.
The chance of having this occur is very low.
chest pain
shortness of breath
feelings of having a fast-beating, fluttering, or pounding heart
Other side effects
injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain
There is no information on the use of the vaccine with other vaccines
FDA tweet about ivermectin
Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection
Epidemiology implicates airborne transmission, aerosol infectiousness
Methods
Confirmed cases gave:
Blood, saliva, mid-turbinate and fomite (phone) swabs
30-minute breath samples while vocalizing
with and without masks
Up to two visits two days apart
Quantified and sequenced viral RNA, cultured virus
Results
N = 49 seronegative cases
Mean days post onset 3.8 ± 2.1
May 2020 through April 2021
Detected SARS-CoV-2 RNA in alpha variant
45% of fine (less than 5 μm) aerosols
31% of coarse ( more than 5 μm) aerosols
65% of fomite samples
Masks reduced viral RNA by:
48% in fine aerosols
77% in coarse aerosols
Cloth and surgical masks were not significantly different
The alpha variant (compared with earlier viruses)
43-fold increase in fine aerosol viral RNA
Remained a significant 18-fold increase adjusting for viral RNA in saliva, swabs, and other potential confounders
Conclusion
SARS-CoV-2 is evolving toward more efficient aerosol generation
Loose-fitting masks provide significant but only modest source control
Continued layered controls and tight-fitting masks and respirators will be necessary
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.